178 related articles for article (PubMed ID: 19888533)
1. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
Agledahl I; Brodin E; Svartberg J; Hansen JB
Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533
[TBL] [Abstract][Full Text] [Related]
2. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
Agledahl I; Brodin E; Svartberg J; Hansen JB
Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
[TBL] [Abstract][Full Text] [Related]
3. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
4. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
Falciani M; Gori AM; Fedi S; Chiarugi L; Simonetti I; Dabizzi RP; Prisco D; Pepe G; Abbate R; Gensini GF; Neri Serneri GG
Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
[TBL] [Abstract][Full Text] [Related]
5. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Bartok A; Steiner S; Seidinger D; Jetzl A; Huber K; Minar E; Stefenelli T; Kopp CW
Thromb Res; 2005; 115(6):469-74. PubMed ID: 15792677
[TBL] [Abstract][Full Text] [Related]
7. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[TBL] [Abstract][Full Text] [Related]
8. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
Adams M; Breckler L; Stevens P; Thom J; Baker R; Oostryck R
Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683
[TBL] [Abstract][Full Text] [Related]
9. Regulation of thrombin generation by TFPI in plasma without and with heparin.
Brodin E; Appelbom H; Osterud B; Hilden I; Petersen LC; Hansen JB
Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
Peverill RE; Teede HJ; Smolich JJ; Malan E; Kotsopoulos D; Tipping PG; McGrath BP
Clin Sci (Lond); 2001 Jul; 101(1):93-9. PubMed ID: 11410120
[TBL] [Abstract][Full Text] [Related]
11. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
Lean SY; Ellery P; Ivey L; Thom J; Oostryck R; Leahy M; Baker R; Adams M
Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease.
Berrettini M; Parise P; Ricotta S; Iorio A; Peirone C; Nenci GG
Thromb Haemost; 1996 Mar; 75(3):395-400. PubMed ID: 8701396
[TBL] [Abstract][Full Text] [Related]
13. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
15. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
Lupu C; Kruithof EK; Kakkar VV; Lupu F
Thromb Haemost; 1999 Dec; 82(6):1652-8. PubMed ID: 10613651
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
Gori AM; Pepe G; Attanasio M; Falciani M; Abbate R; Prisco D; Fedi S; Giusti B; Brunelli T; Giusti B; Brunelli T; Comeglio P; Gensini GF; Neri Serneri GG
Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
[TBL] [Abstract][Full Text] [Related]
17. The effects of pharmacologically induced hypogonadism on mood in healthy men.
Schmidt PJ; Berlin KL; Danaceau MA; Neeren A; Haq NA; Roca CA; Rubinow DR
Arch Gen Psychiatry; 2004 Oct; 61(10):997-1004. PubMed ID: 15466673
[TBL] [Abstract][Full Text] [Related]
18. Thrombin generation in vitro and in vivo, and disturbed tissue factor regulation in patients with acute pancreatitis.
Lindström OK; Tukiainen EM; Kylänpää ML; Mentula PJ; Puolakkainen PA; Wartiovaara-Kautto UM; Repo H; Petäjä JM
Pancreatology; 2011; 11(6):557-66. PubMed ID: 22213026
[TBL] [Abstract][Full Text] [Related]
19. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels.
Dougherty RH; Rohrer JL; Hayden D; Rubin SD; Leder BZ
Clin Endocrinol (Oxf); 2005 Feb; 62(2):228-35. PubMed ID: 15670201
[TBL] [Abstract][Full Text] [Related]
20. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
